Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2010
03/23/2010US7683108 Stability and ejection stability and capable of forming images with fastness, abrasion resistance, color developability, and high density with little feathering
03/23/2010US7683080 purification from sulfide/sulfone derivatives; crystallization; proton pump inhibitors
03/23/2010US7683054 solid oral dosage form comprising about 75 to 600 mg of aliskiren or a hemi-fumarate salt thereof; maximum plasma concentration of drug from 26 to 420 ng/mL between 1 and 3 hours after administering; renin inhibitor; antihypertensives for treating congestive heart failure; industrial scale manufacture
03/23/2010US7683041 Microgel particles for the delivery of bioactive materials
03/23/2010US7683039 Water soluble, randomly substituted partial N-, partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
03/23/2010US7683035 Method of stabilizing and/or isolating nucleic acids
03/23/2010US7683029 high volatility carrier which protects the insulin from thermal degradation upon vaporization, particularly ethanol and water; propellant free.
03/23/2010US7683024 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
03/23/2010US7682635 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
03/23/2010US7682634 Pharmaceutical compositions
03/23/2010US7682633 Multilayer pellets containing water-soluble core, antagonist layer comprising naltrexone HCl coating, cationic sequestering polymer layer, agonist layer comprising morphine sulfate, and osmotic pressure regulating agent layer comprising sodium chloride
03/23/2010US7682632 Tamper-resistant oral opioid agonist formulations
03/23/2010US7682631 Adhesin-specific nanoparticles and process for using same
03/23/2010US7682630 Antitumor agent that forms polymeric micelle complex of low molecule weight antitumor agent with styrene maleic acid copolymer; formed in polymeric micelle complex by intermolecular bonding or mutual interaction between styrene maleic acid copolymer and antitumor agent; reduced side effects
03/23/2010US7682629 tablet comprising hydroxymethylcellulose and gas-generating system
03/23/2010US7682628 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
03/23/2010US7682627 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
03/23/2010US7682626 Polyvinylethers for delivery of polynucleotides to mammalian cells
03/23/2010US7682625 Comprising hydrolyzed gelatin/tryptophan and ingestible carrier; for decubitus ulcers/bariatric surgery
03/23/2010US7682624 Method for treating wounds to promote healing
03/23/2010US7682623 Pharmaceutical composition for topical application
03/23/2010US7682620 Oil-containing biliquid foam dispersed in a salt-containing aqueous phase having a pH of less than about 7, is gelled by a polymeric sulfonic acid, e.g., ammonium acrylamidopropanesulfonic acid-vinylformamide copolymer
03/23/2010US7682606 Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates
03/23/2010US7682540 Method of making hydrogel implants
03/23/2010US7682387 Drug-delivery endovascular stent and method for treating restenosis
03/23/2010US7682356 Osmotic delivery systems and piston assemblies for use therein
03/23/2010US7682355 Refined infection monitoring
03/23/2010US7682354 Dispenser having piezoelectric elements and method of operation
03/23/2010CA2524074C Oral composition to reduce cold symptoms and duration of same
03/23/2010CA2491572C Abuse-deterrent pharmaceutical compositions of opiods and other drugs
03/23/2010CA2460676C Implantable fluid delivery apparatuses and implantable electrode
03/23/2010CA2424656C Composition and method for stable injectable liquids
03/23/2010CA2421240C Granular preparations for oral administration
03/23/2010CA2408992C Pharmaceutical preparation for the diagnosis of helicobacter pylori infection
03/23/2010CA2401000C Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
03/23/2010CA2399405C 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
03/23/2010CA2396702C N,o-amidomalonate platinum complexes
03/23/2010CA2389928C Method for treating diabetes
03/23/2010CA2389251C Swelling and deswelling polymer blends
03/23/2010CA2380951C Pharmaceutical compositions for oral and topical administration
03/23/2010CA2377783C Epitopes formed by non-covalent association of conjugates
03/23/2010CA2372994C Implantable gel compositions and method of manufacture
03/23/2010CA2364742C Anthelmintic composition
03/23/2010CA2360795C Therapeutic compositions containing glutathione analogs
03/23/2010CA2358457C Topical composition comprising n-acetylaldosamines or n-acetylamino acids
03/23/2010CA2325386C Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
03/23/2010CA2311755C Therapeutic formulation for administering tolterodine with controlled release
03/23/2010CA2197982C Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
03/23/2010CA2194797C Nucleic acid containing composition, preparation and uses of same
03/23/2010CA2194448C Method of priming an immune response in a one-day old animal
03/23/2010CA2176927C Transparent liquid for encapsulated drug delivery
03/18/2010WO2010030868A1 Solvent extraction microencapsulation with tunable extraction rates
03/18/2010WO2010030739A1 Polyethylene glycol lipid conjugates and uses thereof
03/18/2010WO2010030735A2 Stabilized coating for pharmaceutical formulations
03/18/2010WO2010030730A1 Polyethylene glycol lipid conjugates and uses thereof
03/18/2010WO2010030667A2 Dosage forms for weakly ionizable compounds
03/18/2010WO2010030636A1 Low ph retinoid topical compositions
03/18/2010WO2010030598A2 Pharmaceutical formulations comprising pemetrexed
03/18/2010WO2010030506A1 Systems and methods for modeling of crystallization processes
03/18/2010WO2010030342A2 Heparosan polymers and methods of making and using same for the enhancement of therapeutics
03/18/2010WO2010029951A1 Orally administrable formulation containing branched chain amino acid
03/18/2010WO2010029930A1 Stable pharmaceutical formulation with limited discoloration
03/18/2010WO2010029571A2 Modified release ramipril compositions and uses thereof
03/18/2010WO2010029517A1 Vinyl alcohol co-polymer cryogels, vinyl alcohol co-polymers, and methods and products thereof
03/18/2010WO2010029500A1 Chelating amphiphilic polymers
03/18/2010WO2010029469A1 Drug carrier providing mri contrast enhancement
03/18/2010WO2010029441A2 Nasal delivery
03/18/2010WO2010029433A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion
03/18/2010WO2010029374A1 Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
03/18/2010WO2010029335A1 Method for delivering a pharmaceutical composition to patient in need thereof
03/18/2010WO2010029307A1 Medical product
03/18/2010WO2010029095A2 Capsule with soluble blocking element
03/18/2010WO2010029093A2 Compositions for percutaneous administration
03/18/2010WO2010029038A1 Controlled-release nimesulide composition
03/18/2010WO2010029037A1 Orally dispersible nimesulide composition
03/18/2010WO2010028846A1 Treatment of acute myocardial infarction (ami) using encapsulated cells encoding and secreting glp-1 peptides or analogs thereof
03/18/2010WO2010028843A1 Tablets for subsequent nanoparticle suspension filling using ultrasound
03/18/2010WO2010028826A2 A method for the production of bioadhesive compact matrices that can be used either as such or for the prolonged release of active substances, and compact matrices thus obtained
03/18/2010WO2010028794A1 Retard tablets containing quetiapine
03/18/2010WO2010028596A1 The pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof
03/18/2010WO2010028515A2 A pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, ointment, solution, emulsion, liposome and microcapsule form
03/18/2010WO2010028489A1 Starch-based microparticles for the release of agents disposed therein
03/18/2010WO2010028488A1 Apparatus and method for dehydrating biological materials with freezing and microwaving
03/18/2010WO2010011622A9 Ophthalmic gallium compositions and methods of their use
03/18/2010WO2010010470A3 Methods of administering topical antifungal formulations for the treatment of fungal infections
03/18/2010WO2010010257A3 Appetising medicaments for oral administration in solid form for prevention and/or treatment of cardiac insufficiency in animals
03/18/2010WO2010010256A3 Appetising medicament for oral administration in solid form
03/18/2010WO2010010240A3 Dermal patch for applying dry active agents
03/18/2010WO2009140649A8 Rab3b for the treatment and prevention of parkinson's disease
03/18/2010WO2009138170A3 Film-shaped preparation comprising oily substances for oral administration
03/18/2010WO2009136056A3 High-fluidity and non-caking pulverulent crystalline maltitol composition
03/18/2010WO2009129464A4 Method for treating acute pain with a formulated drug depot in combination with a liquid formulation
03/18/2010WO2009129439A4 Medical devices and methods including polymers having biologically active agents therein
03/18/2010WO2009129432A4 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
03/18/2010WO2009126742A3 Enzyme mediated delivery system
03/18/2010WO2009115525A3 Preparation of a pharmaceutical composition for increasing bone mineral density
03/18/2010WO2009105409A3 Dip coated compositions containing a starch having a high amylose content
03/18/2010WO2009095395A3 Pharmaceutical compositions
03/18/2010WO2009077573A3 Suspension comprising non-micronized ezetimibe micro-particles
03/18/2010WO2009063320A3 Solid pharmaceutical composition of ded anosine
1 ... 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 ... 2991